• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risk factors for post-discharge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities
Conclusions COVID-19 inpatients with cardiovascular disease experience high rates of ATE, VTE, or ACM through 90 days post-discharge. Age > 75 years, PAD, CAS, CHF, previous VTE, and ICU admission are independent risk factors.PMID:37146648 | DOI:10.1055/a-2087-3003
Source: Thrombosis and Haemostasis - May 5, 2023 Category: Hematology Authors: Dimitrios Giannis Mark Goldin Husneara Rahman Cristina P Sison Martin Lesser Sam Ngu James Tsang Michael Qiu Shreya Sanghani Jackson Yeh Miltiadis Matsagkas Eleni Arnaoutoglou Alex C Spyropoulos Source Type: research

Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.
Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarct...
Source: Thrombosis and Haemostasis - April 28, 2020 Category: Hematology Authors: Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L Tags: Thromb Haemost Source Type: research

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research

Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets
Platelets. 2021 Jun 7:1-9. doi: 10.1080/09537104.2021.1936478. Online ahead of print.ABSTRACTPlatelets may be a target of bacteria and viruses, which can directly or indirectly activate them so promoting thrombosis. In accordance with this, community-acquired pneumonia (CAP) is complicated by ischemia-related vascular disease (myocardial infarction and stroke) in roughly 10% of patients while the incidence of venous thrombosis is uncertain. In CAP platelet biosynthesis of TxA2 is augmented and associated with myocardial infarction; however, a cause-effect relationship is still unclear as unclear is if platelet activation p...
Source: Platelets - June 7, 2021 Category: Hematology Authors: Francesco Violi Vittoria Cammisotto Pasquale Pignatelli Source Type: research

Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19
AbstractPatients with Coronavirus Disease-2019 (COVID ‐19) have haemostatic dysfunction and are at higher risk of thrombotic complications. Although age is a major risk factor for outcome impairment in COVID-19, its impact on coagulative patterns here is still unclear. We investigated the association of Endogenous Thrombin Potential (ETP) with thromb otic and haemorrhagic events according to different ages in patients admitted for COVID-19. A total of 27 patients with COVID‐19-related pneumonia, without need for intensive care unit admission or mechanical ventilation at hospital presentation, and 24 controls with non-C...
Source: Journal of Thrombosis and Thrombolysis - June 10, 2021 Category: Hematology Source Type: research

Complement dysregulation is associated with severe COVID-19 illness
Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.279155. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may manifest as thrombosis, stroke, renal failure, myocardial infarction, and thrombocytopenia, reminiscent of other complement-mediated diseases. Multiple clinical and preclinical studies have implicated complement in the pathogenesis of COVID-19 illness. We previously found that the SARS-CoV-2 spike protein activates the alternative pathway of complement (APC) in vitro through interfering with the function of complement factor H, a key negative regulator of APC. Here, w...
Source: Haematologica - July 22, 2021 Category: Hematology Authors: Jia Yu Gloria F Gerber Hang Chen Xuan Yuan Shruti Chaturvedi Evan M Braunstein Robert A Brodsky Source Type: research

Platelets and COVID-19
Hamostaseologie. 2021 Oct;41(5):379-385. doi: 10.1055/a-1581-4355. Epub 2021 Oct 25.ABSTRACTIn 2019 first reports about a new human coronavirus emerged, which causes common cold symptoms as well as acute respiratory distress syndrome. The virus was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severe thrombotic events including deep vein thrombosis, pulmonary embolism, and microthrombi emerged as additional symptoms. Heart failure, myocardial infarction, myocarditis, and stroke have also been observed. As main mediator of thrombus formation, platelets became one of the key aspects in SARS-C...
Source: Hamostaseologie - October 25, 2021 Category: Hematology Authors: Anne-Katrin Rohlfing Dominik Rath Tobias Geisler Meinrad Gawaz Source Type: research

Pages: 1  2